Cherukuri Phani B, Ravilla Jayasree, Yarrarapu Siva N S, Turtel Penny, Doantrang Du
Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA.
Department of Gastroenterology, Monmouth Medical Center, New Jersey, USA.
J Community Hosp Intern Med Perspect. 2025 Mar 7;15(2):85-89. doi: 10.55729/2000-9666.1465. eCollection 2025.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease, often involves extraintestinal manifestations, affecting up to 40% of patients. Cardiovascular complications, although rare, can include pericarditis, the most common cardiac manifestation in IBD.
We report the case of a 34-year-old male with a long-standing history of UC who presented with pleuritic chest pain, shortness of breath, and worsening colitis symptoms. This case is particularly noteworthy due to the complexity added by the patient's 24-year history of UC, diverse treatment modalities (including mesalamine, 6-mercaptopurine, infliximab, vedolizumab, upadacitinib, and ustekinumab), and the patient not being on any 5-aminosalicylic acid (5-ASA) medications known to cause pericarditis at the time of presentation. The pericarditis episodes were temporally associated with UC flare-ups, complicating the distinction between disease-induced and medication-induced pericarditis. The patient experienced two recurrent episodes within 14 weeks, and comprehensive investigations excluded other common causes, narrowing down the potential etiologies. Clinical evaluation revealed pericarditis with a moderate pericardial effusion, elevated inflammatory markers, and normal cardiac biomarkers. The patient's pericarditis was managed with corticosteroids and colchicine, leading to rapid symptom resolution. This case underscores the challenge of distinguishing between disease-induced and medication-induced pericarditis in IBD patients.
Pericarditis, although a rare extraintestinal manifestation of IBD, should be considered in patients with UC presenting with chest pain. This report highlights the need for heightened awareness and careful management of pericarditis in UC patients. Clinicians should maintain a high index of suspicion for cardiovascular complications in IBD, ensuring timely diagnosis and intervention.
炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病,常伴有肠外表现,影响多达40%的患者。心血管并发症虽然罕见,但可包括心包炎,这是IBD中最常见的心脏表现。
我们报告一例34岁男性,有长期UC病史,出现胸膜炎性胸痛、呼吸急促和结肠炎症状加重。该病例特别值得注意,因为患者有24年的UC病史,采用了多种治疗方式(包括美沙拉嗪、6-巯基嘌呤、英夫利昔单抗、维多珠单抗、乌帕替尼和乌司奴单抗),且在就诊时未服用任何已知会引起心包炎的5-氨基水杨酸(5-ASA)药物。心包炎发作与UC病情发作在时间上相关,使得区分疾病诱发的和药物诱发的心包炎变得复杂。患者在14周内经历了两次复发,全面检查排除了其他常见病因,缩小了潜在病因范围。临床评估显示心包炎伴中度心包积液、炎症标志物升高和心脏生物标志物正常。患者的心包炎采用皮质类固醇和秋水仙碱治疗,症状迅速缓解。该病例强调了在IBD患者中区分疾病诱发的和药物诱发的心包炎的挑战。
心包炎虽然是IBD罕见的肠外表现,但对于出现胸痛的UC患者应予以考虑。本报告强调了提高对UC患者心包炎的认识并进行仔细管理的必要性。临床医生应高度怀疑IBD患者的心血管并发症,确保及时诊断和干预。